Cis-platinum (CDDP) plus etoposide (VP-16-213) and treatment of disseminated neuroblastoma.
Ten patients with neuroblastoma were treated with a standard pulsed administration schedule of cis-platinum and etoposide (VP16-213). Two patients are experiencing good partial responses lasting over 8 months. One other patient had a partial response. Toxicity was mild and limited to high frequency hearing loss, temporary increase in blood urea nitrogen, and myelosuppression. These data may be useful to compare with data from other more aggressive or different administration schedules of the drug combination.
D000328:Adult; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D005047:Etoposide; D002945:Cisplatin